1.Adjuvant chemotherapy of colorectal carcinoma: Capecitabine Tablets are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. It was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent Capecitabine in the adjuvant treatment of Dukes’ C colon cancer.

2. Colorectal carcinoma: Capecitabine monotherapy or in combination with oxaliplatin are indicated as first-line treatment of patients with metastatic colorectal carcinoma.

3. Combination chemotherapy of breast cancer: Capecitabine in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

4. Single chemotherapy of breast cancer: Capecitabine monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracyclinecontaining adjuvant regimen.

5. Gastric cancer: Capecitabine is indicated as first-line treatment of patients with inoperable advanced or metastatic gastric cancer.